Clinical Trial Update: Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial examining the combination of fulvestrant, ipatasertib, and a CDK4/6 inhibitor in metastatic estrogen receptor-positive, HER2-negative b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor-positive Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor
• Fulvestrant (fulvestrant)
• ipatasertib (ipatasertib)

Snippet

Sponsor: Royal Marsden NHS Foundation Trust | Conditions: Metastatic Breast Cancer, ER+ Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING